{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:26:36Z","timestamp":1788143196483,"version":"build-2803163510"},"reference-count":29,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,24]]},"DOI":"10.20945\/2359-4292-2023-0242","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T13:25:31Z","timestamp":1716816331000},"source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review"],"prefix":"10.20945","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6658-0269","authenticated-orcid":false,"given":"Manjunath Havalappa","family":"Dodamani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7329-5027","authenticated-orcid":false,"given":"Samantha","family":"Cheryl Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2951-8861","authenticated-orcid":false,"given":"Samiksha","family":"Bhattacharjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7612-506X","authenticated-orcid":false,"given":"Rohit","family":"Barnabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7072-1896","authenticated-orcid":false,"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7097-2831","authenticated-orcid":false,"given":"Anurag Ranjan","family":"Lila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5199-6299","authenticated-orcid":false,"given":"Saba Samad","family":"Memon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7277-7052","authenticated-orcid":false,"given":"Manjiri","family":"Karlekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-6809","authenticated-orcid":false,"given":"Virendra A.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6902-4639","authenticated-orcid":false,"given":"Tushar R.","family":"Bandgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"issue":"7","key":"key20240527132527_B1","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician's guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res. 2011 Jul;26(7):1381-8. doi: 10.1002\/jbmr.340.","journal-title":"J Bone Miner Res"},{"key":"key20240527132527_B2","doi-asserted-by":"crossref","first-page":"17101","DOI":"10.1038\/nrdp.2017.101","article-title":"Rickets","volume":"3","author":"Carpenter","year":"2017","unstructured":"Carpenter TO, Shaw NJ, Portale AA, Ward LM, Abrams SA, Pettifor JM. Rickets. Nat Rev Dis Primer. 2017 Dec 21;3:17101. doi: 10.1038\/nrdp.2017.101.","journal-title":"Nat Rev Dis Primer"},{"issue":"1","key":"key20240527132527_B3","first-page":"17","article-title":"FGF23 and Associated Disorders of Phosphate Wasting","volume":"17","author":"Gohil","year":"2019","unstructured":"Gohil A, Imel EA. FGF23 and Associated Disorders of Phosphate Wasting. Pediatr Endocrinol Rev. 2019 Sep;17(1):17-34. doi: 10.17458\/per.vol17.2019.gi.fgf23anddisordersphosphate.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"1","key":"key20240527132527_B4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G, et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. 2019 Feb 26;14(1):58. doi: 10.1186\/s13023-019-1014-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"key20240527132527_B5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00223-020-00692-5","article-title":"Congenital Conditions of Hypophosphatemia in Children","volume":"108","author":"Imel","year":"2021","unstructured":"Imel EA. Congenital Conditions of Hypophosphatemia in Children. Calcif Tissue Int. 2021 Jan;108(1):74-90. doi: 10.1007\/s00223-020-00692-5.","journal-title":"Calcif Tissue Int"},{"issue":"0 2","key":"key20240527132527_B6","first-page":"367","article-title":"The changing face of hypophosphatemic disorders in the FGF-23 era","volume":"10","author":"Lee","year":"2013","unstructured":"Lee JY, Imel EA. The changing face of hypophosphatemic disorders in the FGF-23 era. Pediatr Endocrinol Rev. 2013 Jun;10 Suppl 2(0 2):367-79.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"6","key":"key20240527132527_B7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00005792-198911000-00002","article-title":"X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults","volume":"68","author":"Reid","year":"1989","unstructured":"Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP. X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine (Baltimore). 1989 Nov;68(6):336-52.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"key20240527132527_B8","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014 Mar 14;3(1):R13-30. doi: 10.1530\/EC-13-0103.","journal-title":"Endocr Connect"},{"issue":"8","key":"key20240527132527_B9","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"M\u00e4kitie","year":"2003","unstructured":"M\u00e4kitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 2003 Aug;88(8):3591-7. doi: 10.1210\/jc.2003-030036.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20240527132527_B10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00467-010-1705-9","article-title":"Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets","volume":"26","author":"Zivi\u010dnjak","year":"2011","unstructured":"Zivi\u010dnjak M, Schnabel D, Billing H, Staude H, Filler G, Querfeld U, et al. Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatr Nephrol. 2011 Feb;26(2):223-31. doi: 10.1007\/s00467-010-1705-9.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"key20240527132527_B11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00860736","article-title":"Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease","volume":"9","author":"Taylor","year":"1995","unstructured":"Taylor A, Sherman NH, Norman ME. Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease. Pediatr Nephrol. 1995 Apr;9(2):173-5. doi: 10.1007\/BF00860736.","journal-title":"Pediatr Nephrol"},{"key":"key20240527132527_B12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bone.2019.06.025","article-title":"Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients","volume":"127","author":"DeLacey","year":"2019","unstructured":"DeLacey S, Liu Z, Broyles A, El-Azab SA, Guandique CF, James BC, et al. Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients. Bone. 2019 Oct;127:386-92. doi: 10.1016\/j.bone.2019.06.025.","journal-title":"Bone"},{"issue":"4","key":"key20240527132527_B13","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1210\/jc.2009-1671","article-title":"Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations","volume":"95","author":"Imel","year":"2010","unstructured":"Imel EA, DiMeglio LA, Hui SL, Carpenter TO, Econs MJ. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab. 2010 Apr;95(4):1846-50. doi: 10.1210\/jc.2009-1671.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"key20240527132527_B14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults with X-Linked Hypophosphatemia: Week 24 Primary Analysis","volume":"33","author":"Insogna","year":"2018","unstructured":"Insogna KL, Briot K, Imel EA, Kamenick\u00fd P, Ruppe MD, Portale AA, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults with X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res. 2018 Aug;33(8):1383-93. doi: 10.1002\/jbmr.3475.","journal-title":"J Bone Miner Res"},{"issue":"21","key":"key20240527132527_B15","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab Therapy in Children with X-Linked Hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, H\u00f6gler W, Linglart A, et al. Burosumab Therapy in Children with X-Linked Hypophosphatemia. N Engl J Med. 2018 May 24;378(21):1987-98. doi: 10.1056\/NEJMoa1714641.","journal-title":"N Engl J Med"},{"issue":"10189","key":"key20240527132527_B16","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","unstructured":"Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019 Jun 15;393(10189):2416-27. doi: 10.1016\/S0140-6736(19)30654-3.","journal-title":"Lancet"},{"issue":"3","key":"key20240527132527_B17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","unstructured":"Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, et al. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019 Mar;7(3):189-99. doi: 10.1016\/S2213-8587(18)30338-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"key20240527132527_B18","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","unstructured":"Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014 Apr;124(4):1587-97. doi: 10.1172\/JCI72829.","journal-title":"J Clin Invest"},{"issue":"3","key":"key20240527132527_B19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/tropej\/46.3.132","article-title":"Radiographic scoring method for the assessment of the severity of nutritional rickets","volume":"46","author":"Thacher","year":"2000","unstructured":"Thacher TD, Fischer PR, Pettifor JM, Lawson JO, Manaster BJ, Reading JC. Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr. 2000 Jun;46(3):132-9. doi: 10.1093\/tropej\/46.3.132.","journal-title":"J Trop Pediatr"},{"key":"key20240527132527_B20","doi-asserted-by":"crossref","first-page":"115964","DOI":"10.1016\/j.bone.2021.115964","article-title":"Validation of the Radiographic Global Impression of Change (RGI-C) score to assess healing of rickets in pediatric X-linked hypophosphatemia (XLH)","volume":"148","author":"Lim","year":"2021","unstructured":"Lim R, Shailam R, Hulett R, Skrinar A, Nixon A, Williams A, et al. Validation of the Radiographic Global Impression of Change (RGI-C) score to assess healing of rickets in pediatric X-linked hypophosphatemia (XLH). Bone. 2021 Jul;148:115964. doi: 10.1016\/j.bone.2021.115964.","journal-title":"Bone"},{"key":"key20240527132527_B21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2288-14-30","article-title":"Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference?","volume":"14","author":"Takeshima","year":"2014","unstructured":"Takeshima N, Sozu T, Tajika A, Ogawa Y, Hayasaka Y, Furukawa TA. Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference? BMC Med Res Methodol. 2014 Feb 21;14:30. doi: 10.1186\/1471-2288-14-30.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"key20240527132527_B22","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00198-021-06221-w","article-title":"The efficacy and safety of different doses of calcitriol combined with neutral phosphate in X-linked hypophosphatemia: a prospective study","volume":"33","author":"Jin","year":"2022","unstructured":"Jin C, Zhang C, Ni X, Zhao Z, Xu L, Wu B, et al. The efficacy and safety of different doses of calcitriol combined with neutral phosphate in X-linked hypophosphatemia: a prospective study. Osteoporos Int J. 2022 Jun;33(6):1385-95. doi: 10.1007\/s00198-021-06221-w.","journal-title":"Osteoporos Int J"},{"issue":"7","key":"key20240527132527_B23","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23","volume":"100","author":"Imel","year":"2015","unstructured":"Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, et al. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. J Clin Endocrinol Metab. 2015 Jul;100(7):2565-73. doi: 10.1210\/jc.2015-1551.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20240527132527_B24","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10074","article-title":"First-in-Asian Phase I Study of the Anti-Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults with X-linked Hypophosphatemia","volume":"3","author":"Cheong","year":"2018","unstructured":"Cheong HI, Yoo HW, Adachi M, Tanaka H, Fujiwara I, Hasegawa Y, et al. First-in-Asian Phase I Study of the Anti-Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults with X-linked Hypophosphatemia. JBMR Plus. 2018 Sep 14;3(2):e10074. doi: 10.1002\/jbm4.10074.","journal-title":"JBMR Plus"},{"issue":"18","key":"key20240527132527_B25","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJM198010303031802","article-title":"Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets","volume":"303","author":"Glorieux","year":"1980","unstructured":"Glorieux FH, Marie PJ, Pettifor JM, Delvin EE. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med. 1980 Oct 30;303(18):1023-31. doi: 10.1056\/NEJM198010303031802.","journal-title":"N Engl J Med"},{"issue":"10","key":"key20240527132527_B26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM197209072871003","article-title":"Use of phosphate and vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia","volume":"287","author":"Glorieux","year":"1972","unstructured":"Glorieux FH, Scriver CR, Reade TM, Goldman H, Roseborough A. Use of phosphate and vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia. N Engl J Med. 1972 Sep 7;287(10):481-7. doi: 10.1056\/NEJM197209072871003.","journal-title":"N Engl J Med"},{"issue":"6","key":"key20240527132527_B27","first-page":"1514","article-title":"Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets","volume":"75","author":"Rivkees","year":"1992","unstructured":"Rivkees SA, el-Hajj-Fuleihan G, Brown EM, Crawford JD. Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab. 1992 Dec;75(6):1514-8. doi: 10.1210\/jcem.75.6.1464657.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"key20240527132527_B28","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial","volume":"34","author":"Insogna","year":"2019","unstructured":"Insogna KL, Rauch F, Kamenick\u00fd P, Ito N, Kubota T, Nakamura A, et al. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial. J Bone Miner Res. 2019 Dec;34(12):2183-91. doi: 10.1002\/jbmr.3843.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"key20240527132527_B29","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia","volume":"107","author":"Linglart","year":"2022","unstructured":"Linglart A, Imel EA, Whyte MP, Portale AA, H\u00f6gler W, Boot AM, et al. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia. J Clin Endocrinol Metab. 2022 Feb 17;107(3):813-24. doi: 10.1210\/clinem\/dgab729.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T13:25:42Z","timestamp":1716816342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/efficacy-and-safety-of-burosumab-compared-with-conventional-therapy-in-patients-with-x-linked-hypophosphatemia-a-systematic-review\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":29,"alternative-id":["10.20945\/2359-4292-2023-0242"],"URL":"https:\/\/doi.org\/10.20945\/2359-4292-2023-0242","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e230242"}}